MyriaScreen Diversity Collection of drug-like screening compounds is now over 50% updated with new and more diverse structural material. New MyriaScreen II carries out the same design approach and combines premium molecular candidates hand-picked from Sigma-Aldrich and TimTec compound stocks. The selection of 10,000 high-purity and diverse molecules is the result of careful evaluation, multi-stage filtering, and refinement of two companiesÃ¢â‚¬â„¢ compound pools.
Superior Structural Diversity and Design
MyriaScreen was created by combining medicinal chemistry and computational expertise and decades of experience in screening collections design, compound synthesis and sourcing. TimTec proprietary software was used to filter a pre-selected pool of over 300,000 TimTec and Sigma-Aldrich compounds on the basis of diversity and structural relevance for general screening.
Additional filters were set to consider physical-chemical properties including MW, cLogP, H-acceptor, H-donors, and rotatable bonds. Molecular weight range is from about 120 to 500. The collection is largely drug-like according to Lipinski Rule of 5 and also includes lead like material being suitable for more targets and leaving greater room for molecular optimization.
The selection was refined with expertsÃ¢â‚¬â„¢ great personal attention to remove compounds that were overly represented or not well suited for medicinal chemistry follow-up. MyriaScreen is rich in chemotypes and a valuable source of screening compounds for lead discovery.
Ready-to-Use Format High purity Efficient Resupply
MyriaScreen II is offered in more pre-plated formatting options to accommodate greater variety of assays. In addition to in-demand 1mg/1mL concentration, MyriaScreen II is now available in 10mMol concentration. The compounds have an average purity > 95% with nothing below 90%. Should you require more material for follow-up, re-supply from stock or re-synthesis is available.
Click herefor more information or to request a MyriaScreen Diversity Collection SDFile.